Dupixent and Cosentyx are two innovative biologic medications that have emerged as key players in the treatment of various chronic inflammatory conditions. Both of these drugs have shown promising results in clinical studies, providing relief to patients suffering from debilitating symptoms associated with conditions such as eczema, asthma, and psoriasis. The introduction of these medications marks a significant advancement in the field of immunology and represents a shift towards targeted therapy that aims to address the underlying causes of these diseases, rather than merely alleviating symptoms. The development of biologics like Dupixent and Cosentyx is rooted in the understanding of the immune system and its role in inflammation. As autoimmune…